Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease.
about
Role of microglia in central nervous system infectionsMatrix Metalloproteinases in Non-Neoplastic Disorders.Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative DiseasesThe potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseProtective Microglia and Their Regulation in Parkinson's DiseaseMultifaceted role of matrix metalloproteinases (MMPs)Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous systemThe Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian ModelsExtracellular regulated kinase 1/2 signaling is a critical regulator of interleukin-1β-mediated astrocyte tissue inhibitor of metalloproteinase-1 expression.Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct STAT target gene.Matrix metalloproteinase-3 causes dopaminergic neuronal death through Nox1-regenerated oxidative stressRole of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death.CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1.Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference.Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation.Associations of Matrix Metalloproteinase-9 and Tissue Inhibitory Factor-1 Polymorphisms With Parkinson Disease in Taiwan.Neurovascular matrix metalloproteinases and the blood-brain barrier.Role of extracellular factors in axon regeneration in the CNS: implications for therapy.Critical role of calpain in spinal cord degeneration in Parkinson's diseaseVitamin B12 deficiency reduces proliferation and promotes differentiation of neuroblastoma cells and up-regulates PP2A, proNGF, and TACE.Whole-exome sequencing of 228 patients with sporadic Parkinson's diseaseKLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species.Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders.Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-α, releasing matrix metalloproteinase-9 and migrating in vitroMMP-9 in translation: from molecule to brain physiology, pathology, and therapy.Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.Molecular changes in the postmortem parkinsonian brain.RNA interference-mediated silencing of laminin receptor 1 (LR1) suppresses migration and invasion and down-regulates matrix metalloproteinase (MMP)-2 and MMP-9 in trophoblast cells: implication in the pathogenesis of preeclampsia.Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-κB signaling pathway.Stimulus-responsive viral vectors for controlled delivery of therapeutics.Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury.Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients.Evaluation of peripheral matrix metalloproteinase-1 in Parkinson's disease: a case-control study.Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease.Doxycycline shows dose-dependent changes in hernia repair strength after mesh repair.
P2860
Q24563024-7BB93796-949B-488C-8103-792A4BFCE40AQ26741827-0E2C3CF1-C5AC-4D1D-819A-3E2FD966B88DQ26779933-9F21EE2A-D53D-4040-AB52-A69D1085CA04Q26853347-8078B737-4349-4185-9E30-0CA65B49BDF2Q28079731-A2989E4F-A630-4E52-A8C5-BE9133E1467EQ28083906-0469872F-6743-4371-B792-549FD496DD6CQ28188647-0258D1D5-B0A2-4AAF-A27A-F62DD6DE1CC9Q33722313-9043EE1E-9658-4C07-A21A-96BC911D8C9CQ34607184-82DE9EC2-3BCD-415D-8968-8E14A41CFE2FQ34651167-8610A82D-6273-451D-9CF0-858784DB488FQ34764783-B1F7AD79-4544-40CB-9CE9-F04DE3C4C9AAQ34800137-6F689EC0-DC92-45AA-9469-BEFE5064D452Q35038078-2D955818-427C-44B8-AFC5-92AEACBF4D38Q35158376-342A72AA-907F-48E6-8BED-3A9F0AC3EA66Q35609611-3056B3A3-F20B-4DE2-B0F5-5DF5B7179ABFQ35721080-EAD9BC3D-5E80-4CF6-80A7-6723C18DEB30Q35939162-BC0DE46A-8858-40C7-AA6E-D2EEA13E0751Q36566963-06A2A424-D3F5-4D37-99CF-DE09B2448B09Q37270697-BCB6A913-A36A-4A05-B178-B0FA9568776AQ37306814-DF148C84-55E2-41DB-8DB8-D5DFE0AC51D2Q37384896-B30BD62B-2A91-4610-8537-F4A8D30FBB19Q37458465-DB9F8C22-2148-4653-B71A-48030A7965ABQ37602056-F32F9AD2-91E1-4E6E-A896-D5C3B7416EBEQ37716380-1FA1B616-2A56-4BC4-82C3-DB6362BA5BDFQ38151704-F1B4E291-8360-47A2-92ED-DED69BD6DC15Q38590785-62D01750-3E31-4E54-AB52-39DF48297A66Q38622769-5654350F-2119-4B71-A0BC-4865561CAE4AQ38870841-223765ED-D37C-4880-B64E-6D724F3D361BQ38887346-F4BDF667-8BB1-428C-9C2E-7F000682B2A5Q39144666-96465C16-155B-4B65-9148-C55EB27EBD7EQ39146438-8A27D80D-CFE1-4751-A3FD-5178A1FA8FA7Q40069936-31E92A4C-B6CF-43C9-9CCF-81A31D41B66DQ42593368-D170C67C-C2AA-43C5-AC39-CC64C4EE4A47Q42908536-CF6ED620-6E88-4D19-932D-658B1514057DQ46929091-95F53105-071F-44E2-B49E-B5810137E683Q47316985-ABE3AF94-89BD-454E-A260-4C5DBBB25082Q48018178-B67A63A8-6FFE-41A5-843C-1386408C847DQ49829727-ED6981A9-AE00-4A75-A47D-5370AC8A3562Q51812714-1190A845-7AD2-4C69-BD2E-0F2D13921E51
P2860
Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Expression of MMP-2, MMP-9, an ...... tissue of Parkinson's disease.
@en
Expression of MMP-2, MMP-9, an ...... tissue of Parkinson's disease.
@nl
type
label
Expression of MMP-2, MMP-9, an ...... tissue of Parkinson's disease.
@en
Expression of MMP-2, MMP-9, an ...... tissue of Parkinson's disease.
@nl
prefLabel
Expression of MMP-2, MMP-9, an ...... tissue of Parkinson's disease.
@en
Expression of MMP-2, MMP-9, an ...... tissue of Parkinson's disease.
@nl
P2093
P356
P1476
Expression of MMP-2, MMP-9, an ...... tissue of Parkinson's disease.
@en
P2093
David S Albers
Jason Chirichigno
M Flint Beal
Sabine Narr
Stefan Lorenzl
P356
10.1006/EXNR.2002.8019
P407
P577
2002-11-01T00:00:00Z